New drug targets cancer enzyme in early human trial
NCT ID NCT06911008
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new drug called MTI-301 in 42 adults with advanced solid cancers that have spread or can't be removed and haven't responded to standard treatments. The drug blocks an enzyme called SCD1, which some cancers use to grow and spread. The main goals are to find the safest dose and check for side effects, while also seeing if the drug can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MTI-301 (a drug that blocks the SCD1 enzyme, which may slow tumor growth)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid cancers that have stopped responding to other therapies.
What could go wrong
This is a very early Phase I trial with only 42 people, focused mainly on safety and dosing. The drug may not shrink tumors or could cause side effects, and it's too soon to know if it will help patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Florida
RECRUITINGJacksonville, Florida, 32224-9980, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact